Toward a Risk-Utility Data Governance Framework for Research Using Genomic and Phenotypic Data in Safe Havens: Multifaceted Review.
Research utilizing genomic information opens up new insights into well being and illness. Being ready to make use of the information in affiliation with well being and administrative report information held in protected havens can multiply the advantages.
Anti-NP Antibody |
|||
Y123088 | ABM | 100 µl | EUR 320 |
Anti-NP (6E5) |
|||
YF-MA20373 | Abfrontier | 100 ug | EUR 435.6 |
Description: Mouse monoclonal to NP |
Anti-AIV NP Antibody |
|||
MBS415325-01mL | MyBiosource | 0.1mL | EUR 440 |
Anti-AIV NP Antibody |
|||
MBS415325-5x01mL | MyBiosource | 5x0.1mL | EUR 1720 |
Anti-AIV NP Antibody |
|||
MBS415046-01mL | MyBiosource | 0.1mL | EUR 440 |
Anti-AIV NP Antibody |
|||
MBS415046-5x01mL | MyBiosource | 5x0.1mL | EUR 1720 |
Anti-NP-5 antibody |
|||
STJ16100267 | St John's Laboratory | 100 µg | EUR 1078.8 |
Anti-AIV NP Antibody |
|||
Y123211 | ABM | 100 µl | EUR 320 |
Anti-AIV NP Antibody |
|||
Y123212 | ABM | 100 µl | EUR 320 |
Anti-Acinus (NP) Antibody |
|||
2241 | Genovis AB | 100ug | EUR 445 |
Anti-Acinus (NP) Antibody |
|||
MBS194017-01mg | MyBiosource | 0.1mg | EUR 495 |
Anti-Acinus (NP) Antibody |
|||
MBS194017-5x01mg | MyBiosource | 5x0.1mg | EUR 2215 |
Anti-MERS-NP(2B7) |
|||
AR12-MA0008 | Abfrontier | 100 ul | EUR 400.8 |
Description: Mouse monoclonal to MERS-NP |
Anti-H1N1-NP(2C3) |
|||
AR12-MA0009 | Abfrontier | 100 ul | EUR 400.8 |
Description: Mouse monoclonal to H1N1-NP |
Anti-Human NP-1 Antibody |
|||
102-P194G | ReliaTech | 100 µg | EUR 245.7 |
Description: Defensins (alpha and beta) are cationic peptides with a broad spectrum of antimicrobial activity that comprise an important arm of the innate immune system. The α-defensins, which include NP-1, NP-2 and NP-3, are distinguished from the β-defensins by the pairing of their three disulfide bonds. In addition to antimicrobial activity, NP-1 exhibits chemotactic activity on dendritic cells. NP-1 is expressed as the C-terminal portion of an inactive precursor protein, which also contains a 19 amino acid N-terminal signal sequence and a 45 amino acid polypeptide. NP-1 contains a six-cysteine motif that forms three intra-molecular disulfide bonds. Recombinant Human NP-1 is a 3.4 kDa protein containing 30 amino acid residues. |
Chimaeric IgM Anti NP Antibody |
|||
GWB-5CE172 | GenWay Biotech | 2 ml | Ask for price |
Chimaeric IgE Anti NP Antibody |
|||
GWB-DF0FC3 | GenWay Biotech | 2 ml | Ask for price |
Chimaeric IgA2 Anti NP Antibody |
|||
GWB-324CD1 | GenWay Biotech | 0.5 mg | Ask for price |
Chimaeric IgG2 Anti NP Antibody |
|||
GWB-4C4D87 | GenWay Biotech | 0.5 mg | Ask for price |
Rabbit Polyclonal Anti-NP Antibody |
|||
TA346671 | Origene Technologies GmbH | 100 µl | Ask for price |
Anti-N (Beijing02), Anti-NP (SARS-CoV) |
|||
MBS432038-01mg | MyBiosource | 0.1mg | EUR 345 |
Anti-N (Beijing02), Anti-NP (SARS-CoV) |
|||
MBS432038-5x01mg | MyBiosource | 5x0.1mg | EUR 1405 |
Anti-NP-I Rabbit pAb |
|||
GB111486 | Wuhan Servicebio Technology | 100 μL | EUR 100 |
anti-MERS-Cov NP (2D2) |
|||
AR12-MA0011 | Abfrontier | 100 ul | EUR 400.8 |
Description: Mouse monoclonal to MERS-CoV NP |
Rabbit anti-EBOV NP pAb |
|||
0301-012 | IBT Bioservices | 100ug | EUR 562.5 |
Description: Affinity purified rabbit polyclonal antibody against EBOV NP (detects EBOV NP in virus-like particles (VLP)) |
Rabbit anti-SUDV NP pAb |
|||
0302-012 | IBT Bioservices | 100ug | EUR 562.5 |
Description: Affinity purified rabbit polyclonal antibody against SUDV NP (detects SUDV NP in virus-like particles (VLP)) |
Rabbit anti-MARV NP pAb |
|||
0303-012 | IBT Bioservices | 100ug | EUR 562.5 |
Description: Affinity purified rabbit polyclonal antibody against MARV NP (detects MARV NP in virus-like particles (VLP)) |
anti-MERS-CoV NP (2C11) |
|||
AR12-MA0010 | Abfrontier | 100 ul | EUR 400.8 |
Description: Mouse monoclonal to MERS-CoV NP |
CHIMERIC HUMAN IgE ANTI NP |
|||
MBS216342-2mL | MyBiosource | 2mL | EUR 945 |
CHIMERIC HUMAN IgE ANTI NP |
|||
MBS216342-5x2mL | MyBiosource | 5x2mL | EUR 4085 |
Anti-influenza A-NP(5D5) |
|||
AR12-MA0007 | Abfrontier | 100 ul | EUR 400.8 |
Description: Mouse monoclonal to influenza A-NP |
Rabbit Anti-Rinder Pest NP (RPR-NP) peptides (421-490aa) antiserum |
|||
RPR12-A | Alpha Diagnostics | 100 ul | EUR 534 |
Recombinant anti-2019-nCoV NP ScFv |
|||
E21-A028-1 | EnoGene | 2019-nCoV-ScFv-Antibody | EUR 416.5 |
Description: 2019-nCoV ScFv Antibody |
Recombinant anti-2019-nCoV NP ScFv |
|||
MBS8574824-005mg | MyBiosource | 0.05mg | EUR 705 |
Recombinant anti-2019-nCoV NP ScFv |
|||
MBS8574824-5x005mg | MyBiosource | 5x0.05mg | EUR 2910 |
Anti-VSV NP/Nucleoprotein Antibody (1004) |
|||
MBS1568608-01mg | MyBiosource | 0.1mg | EUR 405 |
Anti-VSV NP/Nucleoprotein Antibody (1004) |
|||
MBS1568608-5x01mg | MyBiosource | 5x0.1mg | EUR 1520 |
Anti-VSV NP/Nucleoprotein Antibody (1307) |
|||
MBS1568609-01mg | MyBiosource | 0.1mg | EUR 405 |
Anti-VSV NP/Nucleoprotein Antibody (1307) |
|||
MBS1568609-5x01mg | MyBiosource | 5x0.1mg | EUR 1520 |
Anti-VSV NP/Nucleoprotein Antibody (1014) |
|||
MBS1568610-01mg | MyBiosource | 0.1mg | EUR 405 |
Anti-VSV NP/Nucleoprotein Antibody (1014) |
|||
MBS1568610-5x01mg | MyBiosource | 5x0.1mg | EUR 1520 |
Anti-VSV NP/Nucleoprotein Antibody (1001) |
|||
MBS1568611-01mg | MyBiosource | 0.1mg | EUR 405 |
Anti-VSV NP/Nucleoprotein Antibody (1001) |
|||
MBS1568611-5x01mg | MyBiosource | 5x0.1mg | EUR 1520 |
Recombinant Mouse Anti-IAV NP Antibody |
|||
TRI-AB-027 | TRI Biotech | 0.1mg | EUR 1620 |
Rabbit Anti-LCMV NP Polyclonal antibody |
|||
CABT-CS971 | Creative Diagnostics | 100 μl | EUR 720 |
Description: Rabbit |
Anti-NP (Influenza B), rabbit IgG |
|||
MBS432046-01mg | MyBiosource | 0.1mg | EUR 345 |
Anti-NP (Influenza B), rabbit IgG |
|||
MBS432046-5x01mg | MyBiosource | 5x0.1mg | EUR 1405 |
Mouse Anti-Influenza B NP-UNLB |
|||
MBS670330-05mg | MyBiosource | 0.5mg | EUR 265 |
Mouse Anti-Influenza B NP-UNLB |
|||
MBS670330-5x05mg | MyBiosource | 5x0.5mg | EUR 1035 |
Rabbit Anti-Rabies Virus Nucleoprotein (RV-NP) (~56 kda, RV-NP) antiserum |
|||
RBVNP12-S | Alpha Diagnostics | 100 ul | EUR 548.4 |
Anti-SARS-CoV NP Mouse IgG1 Antibody |
|||
A2066-100 | Biovision | 100 µg | EUR 381.6 |
Anti-SARS-CoV NP Mouse IgG2b Antibody |
|||
A2064-100 | Biovision | 100 µg | EUR 381.6 |
Anti-Human NP-1 Goat Polyclonal Antibody |
|||
TA328408 | Origene Technologies GmbH | 100 µg | Ask for price |
Chimaeric Human Igm Anti Np Monoclonal Antibody |
|||
DMABT-48904CI | Creative Diagnostics | 2 ml | EUR 567 |
Description: Human |
Anti-H7N9 Nucleoprotein/NP Antibody, Rabbit MAb |
|||
MBS8105600-002mL | MyBiosource | 0.02mL | EUR 185 |
Anti-H7N9 Nucleoprotein/NP Antibody, Rabbit MAb |
|||
MBS8105600-01mL | MyBiosource | 0.1mL | EUR 385 |
Anti-H7N9 Nucleoprotein/NP Antibody, Rabbit MAb |
|||
MBS8105600-5x01mL | MyBiosource | 5x0.1mL | EUR 1590 |
Anti-H7N9 Nucleoprotein/NP Antibody, Rabbit MAb |
|||
MBS8105601-002mL | MyBiosource | 0.02mL | EUR 185 |
Anti-H7N9 Nucleoprotein/NP Antibody, Rabbit MAb |
|||
MBS8105601-01mL | MyBiosource | 0.1mL | EUR 385 |
Anti-H7N9 Nucleoprotein/NP Antibody, Rabbit MAb |
|||
MBS8105601-5x01mL | MyBiosource | 5x0.1mL | EUR 1590 |
Anti-NP (Measles Virus) Rabbit Polyclonal Antibody |
|||
MBS430528-01mg | MyBiosource | 0.1mg | EUR 385 |
Anti-NP (Measles Virus) Rabbit Polyclonal Antibody |
|||
MBS430528-5x01mg | MyBiosource | 5x0.1mg | EUR 1580 |
Anti-Influenza A virus NP/Nucleoprotein Antibody |
|||
MBS1569257-01mg | MyBiosource | 0.1mg | EUR 405 |
Anti-Influenza A virus NP/Nucleoprotein Antibody |
|||
MBS1569257-5x01mg | MyBiosource | 5x0.1mg | EUR 1520 |
Anti-Influenza A virus NP/Nucleoprotein Antibody |
|||
MBS1569258-01mg | MyBiosource | 0.1mg | EUR 405 |
Anti-Influenza A virus NP/Nucleoprotein Antibody |
|||
MBS1569258-5x01mg | MyBiosource | 5x0.1mg | EUR 1520 |
Anti-SARS-CoV Nucleoprotein / NP Monolonal Antibody |
|||
E-AB-V1341-100uL | Elabscience Biotech | 100uL | EUR 415 |
Description: Unconjugated |
Anti-SARS-CoV Nucleoprotein / NP Monolonal Antibody |
|||
E-AB-V1341-50uL | Elabscience Biotech | 50uL | EUR 250 |
Description: Unconjugated |
Anti-SARS-CoV Nucleoprotein / NP Monolonal Antibody |
|||
E-AB-V1341-each | Elabscience Biotech | each | Ask for price |
Description: Unconjugated |
Rabbit anti-Sudan ebolavirus NP Polyclonal Antibody |
|||
MBS9011326-INQUIRE | MyBiosource | INQUIRE | Ask for price |
Anti-MERS-CoV Nucleoprotein/NP Polyclonal Antibody |
|||
E-AB-V1284-100uL | Elabscience Biotech | 100uL | EUR 250 |
Description: Unconjugated |
Anti-MERS-CoV Nucleoprotein/NP Polyclonal Antibody |
|||
E-AB-V1284-200uL | Elabscience Biotech | 200uL | EUR 415 |
Description: Unconjugated |
Anti-MERS-CoV Nucleoprotein/NP Polyclonal Antibody |
|||
E-AB-V1284-each | Elabscience Biotech | each | Ask for price |
Description: Unconjugated |
Anti-SARS-CoV Nucleoprotein / NP Polyclonal Antibody |
|||
E-AB-V1340-100uL | Elabscience Biotech | 100uL | EUR 415 |
Description: Unconjugated |
Anti-SARS-CoV Nucleoprotein / NP Polyclonal Antibody |
|||
E-AB-V1340-50uL | Elabscience Biotech | 50uL | EUR 250 |
Description: Unconjugated |
Anti-SARS-CoV Nucleoprotein / NP Polyclonal Antibody |
|||
E-AB-V1340-each | Elabscience Biotech | each | Ask for price |
Description: Unconjugated |
Anti-SARS-CoV Nucleoprotein / NP Monoclonal Antibody |
|||
E-AB-V1342-100uL | Elabscience Biotech | 100uL | EUR 415 |
Description: Unconjugated |
Anti-SARS-CoV Nucleoprotein / NP Monoclonal Antibody |
|||
E-AB-V1342-50uL | Elabscience Biotech | 50uL | EUR 250 |
Description: Unconjugated |
Anti-SARS-CoV Nucleoprotein / NP Monoclonal Antibody |
|||
E-AB-V1342-each | Elabscience Biotech | each | Ask for price |
Description: Unconjugated |
Anti-MERS-CoV Nucleoprotein/NP Polyclonal Antibody |
|||
MBS2563982-01mL | MyBiosource | 0.1mL | EUR 275 |
Anti-MERS-CoV Nucleoprotein/NP Polyclonal Antibody |
|||
MBS2563982-02mL | MyBiosource | 0.2mL | EUR 415 |
Anti-MERS-CoV Nucleoprotein/NP Polyclonal Antibody |
|||
MBS2563982-5x02mL | MyBiosource | 5x0.2mL | EUR 1815 |
Anti-SARS-CoV Nucleoprotein/NP Polyclonal Antibody |
|||
MBS2564013-005mL | MyBiosource | 0.05mL | EUR 275 |
Anti-SARS-CoV Nucleoprotein/NP Polyclonal Antibody |
|||
MBS2564013-01mL | MyBiosource | 0.1mL | EUR 415 |
Anti-SARS-CoV Nucleoprotein/NP Polyclonal Antibody |
|||
MBS2564013-5x01mL | MyBiosource | 5x0.1mL | EUR 1815 |
Anti-SARS-CoV Nucleoprotein/NP Monoclonal Antibody |
|||
MBS2564014-005mL | MyBiosource | 0.05mL | EUR 275 |
Anti-SARS-CoV Nucleoprotein/NP Monoclonal Antibody |
|||
MBS2564014-01mL | MyBiosource | 0.1mL | EUR 415 |
Anti-SARS-CoV Nucleoprotein/NP Monoclonal Antibody |
|||
MBS2564014-5x01mL | MyBiosource | 5x0.1mL | EUR 1815 |
Anti-SARS-CoV Nucleoprotein/NP Monoclonal Antibody |
|||
MBS2564015-005mL | MyBiosource | 0.05mL | EUR 275 |
Anti-SARS-CoV Nucleoprotein/NP Monoclonal Antibody |
|||
MBS2564015-01mL | MyBiosource | 0.1mL | EUR 415 |
Anti-SARS-CoV Nucleoprotein/NP Monoclonal Antibody |
|||
MBS2564015-5x01mL | MyBiosource | 5x0.1mL | EUR 1815 |
Anti-Sudan ebolavirus/SEBOV NP/Nucleoprotein Antibody |
|||
MBS1569620-01mg | MyBiosource | 0.1mg | EUR 405 |
Anti-Sudan ebolavirus/SEBOV NP/Nucleoprotein Antibody |
|||
MBS1569620-5x01mg | MyBiosource | 5x0.1mg | EUR 1520 |
Anti-influenza B (NP) mAb (4D5), biotin |
|||
4406-6-100 | Mabtech AB | 100 µg | EUR 487.2 |
Anti-influenza A (NP) mAb (19C10), biotin |
|||
4405-6-100 | Mabtech AB | 100 µg | EUR 487.2 |
Rat Anti-nCOV-19 Nucleoprotein (NP) Ab |
|||
MBS122271-01mg | MyBiosource | 0.1mg | EUR 190 |
Rat Anti-nCOV-19 Nucleoprotein (NP) Ab |
|||
MBS122271-1mg | MyBiosource | 1mg | EUR 320 |
Rat Anti-nCOV-19 Nucleoprotein (NP) Ab |
|||
MBS122271-5x01mg | MyBiosource | 5x0.1mg | EUR 780 |
Rat Anti-nCOV-19 Nucleoprotein (NP) Ab |
|||
MBS122272-01mg | MyBiosource | 0.1mg | EUR 190 |
Rat Anti-nCOV-19 Nucleoprotein (NP) Ab |
|||
MBS122272-1mg | MyBiosource | 1mg | EUR 320 |
Rat Anti-nCOV-19 Nucleoprotein (NP) Ab |
|||
MBS122272-5x01mg | MyBiosource | 5x0.1mg | EUR 780 |
Mouse Anti-nCOV-19 Nucleoprotein (NP) Ab |
|||
MBS122269-01mg | MyBiosource | 0.1mg | EUR 190 |
Mouse Anti-nCOV-19 Nucleoprotein (NP) Ab |
|||
MBS122269-1mg | MyBiosource | 1mg | EUR 320 |
Mouse Anti-nCOV-19 Nucleoprotein (NP) Ab |
|||
MBS122269-5x01mg | MyBiosource | 5x0.1mg | EUR 780 |
Mouse Anti-nCOV-19 Nucleoprotein (NP) Ab |
|||
MBS122270-01mg | MyBiosource | 0.1mg | EUR 190 |
Mouse Anti-nCOV-19 Nucleoprotein (NP) Ab |
|||
MBS122270-1mg | MyBiosource | 1mg | EUR 320 |
Mouse Anti-nCOV-19 Nucleoprotein (NP) Ab |
|||
MBS122270-5x01mg | MyBiosource | 5x0.1mg | EUR 780 |
Mouse Anti-nCOV-19 Nucleoprotein (NP) Ab |
|||
MBS122277-01mg | MyBiosource | 0.1mg | EUR 190 |
Mouse Anti-nCOV-19 Nucleoprotein (NP) Ab |
|||
MBS122277-1mg | MyBiosource | 1mg | EUR 320 |
Mouse Anti-nCOV-19 Nucleoprotein (NP) Ab |
|||
MBS122277-5x01mg | MyBiosource | 5x0.1mg | EUR 780 |
Anti-influenza B (NP) mAb (4D5), unconjugated |
|||
4406-5-100 | Mabtech AB | 100 µg | EUR 369.6 |
Anti-influenza A (NP) mAb (19C10), unconjugated |
|||
4405-5-100 | Mabtech AB | 100 µg | EUR 369.6 |
Anti-SARS-CoV-2 NP/Nucleoprotein Nanobody |
|||
MBS1568304-01mg | MyBiosource | 0.1mg | EUR 405 |
Anti-SARS-CoV-2 NP/Nucleoprotein Nanobody |
|||
MBS1568304-5x01mg | MyBiosource | 5x0.1mg | EUR 1520 |
Anti-SARS-CoV-2 NP/Nucleoprotein Nanobody |
|||
MBS1568305-01mg | MyBiosource | 0.1mg | EUR 405 |
Anti-SARS-CoV-2 NP/Nucleoprotein Nanobody |
|||
MBS1568305-5x01mg | MyBiosource | 5x0.1mg | EUR 1520 |
Anti-SARS-CoV-2 NP/Nucleoprotein Nanobody |
|||
MBS1568306-01mg | MyBiosource | 0.1mg | EUR 405 |
Anti-SARS-CoV-2 NP/Nucleoprotein Nanobody |
|||
MBS1568306-5x01mg | MyBiosource | 5x0.1mg | EUR 1520 |
Goat Anti-Peste des petits ruminants NP IgG (PPR-NP) negative control serum |
|||
RV-400805-01N | Alpha Diagnostics | 1 ml | EUR 196.8 |
Camel Anti-Peste des petits ruminants NP (PPR-NP) IgG negative control serum |
|||
RV-400820-05N | Alpha Diagnostics | 1 ml | Ask for price |
Human Anti-SARS CoV/CoV 2 NP Antibody |
|||
E2S209903 | EnoGene | 100ul | EUR 595 |
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody |
NP antibody |
|||
10R-10293 | Fitzgerald | 100 ug | EUR 451 |
Description: Mouse monoclonal NP antibody |
NP Antibody |
|||
MBS7053101-005mg | MyBiosource | 0.05mg | EUR 190 |
NP Antibody |
|||
MBS7053101-01mg | MyBiosource | 0.1mg | EUR 270 |
NP Antibody |
|||
MBS7053101-5x01mg | MyBiosource | 5x0.1mg | EUR 1205 |
NP Antibody |
|||
MBS7103897-005mg | MyBiosource | 0.05mg | EUR 190 |
NP Antibody |
|||
MBS7103897-01mg | MyBiosource | 0.1mg | EUR 270 |
NP Antibody |
|||
MBS7103897-5x01mg | MyBiosource | 5x0.1mg | EUR 1205 |
NP Antibody |
|||
1-CSB-PA529597LA01IMP | Cusabio |
|
|
Description: A polyclonal antibody against NP. Recognizes NP from Influenza A virus. This antibody is Unconjugated. Tested in the following application: ELISA |
NP Antibody |
|||
1-CSB-PA841983HA01RCI | Cusabio |
|
|
Description: A polyclonal antibody against NP. Recognizes NP from Reston ebolavirus. This antibody is Unconjugated. Tested in the following application: ELISA, WB; Recommended dilution: WB:1:500-1:5000 |
NP Antibody |
|||
CAC11098-100ug | Biomatik Corporation | 100ug | EUR 314 |
NP Antibody |
|||
CAC11098-50ug | Biomatik Corporation | 50ug | EUR 199.2 |
NP Antibody |
|||
1-CSB-PA325769LA01IIM | Cusabio |
|
|
Description: A polyclonal antibody against NP. Recognizes NP from Influenza A virus. This antibody is Unconjugated. Tested in the following application: ELISA, WB; Recommended dilution: WB:1:500-1:5000 |
NP Antibody |
|||
1-CSB-PA356056LA01IFZ | Cusabio |
|
|
Description: A polyclonal antibody against NP. Recognizes NP from Influenza A virus. This antibody is Unconjugated. Tested in the following application: ELISA |
NP Antibody |
|||
1-CSB-PA356318HA01IJU | Cusabio |
|
|
Description: A polyclonal antibody against NP. Recognizes NP from Influenza B virus. This antibody is Unconjugated. Tested in the following application: ELISA |
NP Antibody |
|||
1-CSB-PA361330LA01IJK | Cusabio |
|
|
Description: A polyclonal antibody against NP. Recognizes NP from Influenza B virus. This antibody is Unconjugated. Tested in the following application: ELISA |
NP antibody |
|||
70R-18931 | Fitzgerald | 50 ul | EUR 289 |
Description: Rabbit polyclonal NP antibody |
NP antibody |
|||
70R-2286 | Fitzgerald | 50 ug | EUR 467 |
Description: Rabbit polyclonal NP antibody raised against the middle region of NP |
NP Antibody |
|||
GWB-MR164B | GenWay Biotech | 50ug | Ask for price |
NP Antibody |
|||
E551059-11-PU | EnoGene | 100ug | EUR 295 |
Description: Available in various conjugation types. |
NP Antibody |
|||
E309899 | EnoGene | 200ul | EUR 275 |
Description: Available in various conjugation types. |
However, there may be a lot dialogue concerning the use of genomic information with perceptions of specific challenges in doing so safely and successfully.This research aimed to work towards a risk-utility information governance framework for analysis utilizing genomic and phenotypic information in an anonymized kind for analysis in protected havens.
We carried out a multifaceted evaluation drawing upon information governance preparations in revealed analysis, case research of organizations working with genomic and phenotypic information, public views and expectations, and instance research utilizing genomic and phenotypic information in mixture. The findings have been contextualized in opposition to a backdrop of legislative and regulatory necessities and used to create suggestions. We proposed suggestions towards a risk-utility mannequin with a versatile suite of controls to safeguard privateness and retain information utility for analysis.
These have been introduced as overarching rules aligned to the core parts in the information sharing framework produced by the Global Alliance for Genomics and Health and as sensible management measures distilled from revealed literature and case research of operational protected havens to be utilized as required at a project-specific stage.
The suggestions introduced can be utilized to contribute towards a proportionate information governance framework to advertise the protected, socially acceptable use of genomic and phenotypic information in protected havens. They don’t purport to eradicate threat however suggest case-by-case evaluation with transparency and accountability. If the dangers are adequately understood and mitigated, there needs to be no cause that linked genomic and phenotypic information shouldn’t be used in an anonymized kind for analysis in protected havens.